Literature DB >> 11446315

[The value of qualitative regression grading as a prognostic factor for survival after preoperative radiochemotherapy in patients with advanced head and neck cancer].

R M Hermann1, R Krech, J Hartlapp, E Esser, B Christoph, M K Müller, W Wagner.   

Abstract

BACKGROUND: Multimodal therapeutic strategies gain importance in locally advanced squamous cell carcinoma of the head and neck. Quantitative regression grading can be traced as an independent prognostic parameter in the histological examination in many neoadjuvantly treated cancers. Various regression systems have been suggested. We propose an easy to apply and economical score that seems to have a significant prognostic value in squamous cell carcinoma of the head and neck. PATIENTS AND METHODS: 43 patients with Stage IV squamous cell carcinoma of the head and neck have been treated neoadjuvantly with two cycles chemotherapy (ifosfamide 1.5 g/m2 day 1-5 with mesna [300 mg/m2], cisplatin 60 mg/m2 day 5, second cycle day 22). Hyperfractionated accelerated radiotherapy (30 Gy) was given from day 29 on. We divided the resected tumors histologically as follows: Grade I--no tumor cells to be identified, Grade II--necrosis, Grade III--partial destruction of the carcinoma, Grade IV--vital carcinoma.
RESULTS: After 1 year the overall survival amounted to 79%, after 2 years 56%. A significant correlation could be established between qualitative tumor regression and survival. The 1-year survival depended on the regression of the primary as follows: 94% in Grade I, 80% in Grade II, 60% in Grade III and 56% in Grade IV. For the 2-year survival: 76%, 40%, 40%, 11% (p < 0.01). The results were similar regarding the neck dissections.
CONCLUSIONS: After radiochemotherapy the histological regression is a significant prognostic factor of survival. A simple system with four subgroups is suggested which seems to be of a high prognostic value. We discuss to intensify the treatment for patients with good regression after neoadjuvant therapy for a further reduction of recurrence.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11446315     DOI: 10.1007/pl00002408

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  4 in total

1.  [Regression of oesophageal carcinomas after neoadjuvant radiochemotherapy: criteria of the histopathological evaluation].

Authors:  S E Baldus; S P Mönig; W Schröder; R Metzger; S Lang; T K Zirbes; J Thiele; R P Müller; H P Dienes; A H Hölscher; P M Schneider
Journal:  Pathologe       Date:  2004-11       Impact factor: 1.011

2.  Outcome and histopathologic regression in oral squamous cell carcinoma after preoperative radiochemotherapy.

Authors:  Oliver Driemel; Tobias Ettl; Oliver Kölbl; Torsten E Reichert; Bernd V Dresp; Jürgen Reuther; Hans Pistner
Journal:  Strahlenther Onkol       Date:  2009-05-15       Impact factor: 3.621

3.  Histopathologic tumor response after induction chemotherapy and stereotactic body radiation therapy for borderline resectable pancreatic cancer.

Authors:  Michael D Chuong; Jessica M Frakes; Nicholas Figura; Sarah E Hoffe; Ravi Shridhar; Eric A Mellon; Pamela J Hodul; Mokenge P Malafa; Gregory M Springett; Barbara A Centeno
Journal:  J Gastrointest Oncol       Date:  2016-04

4.  Neoadjuvant radiotherapy of head and neck carcinoma: an obstacle for plastic reconstruction?

Authors:  Stefan Riml; Franz Böhler; Lorenz Larcher; Alexander de Vries; Wolfgang Elsässer; Peter Kompatscher
Journal:  Wien Klin Wochenschr       Date:  2012-08-01       Impact factor: 1.704

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.